Connect with us
Most private market investors expect to make more money in 2022—but they’re getting less optimistic | Fortune You need to enable JavaScript to view this site.
Are the good times over for late-stage valuations? Not yet. Read More
Boosted by the COVID vaccine, Moderna’s valuation has now leapfrogged that of well-established Big Pharma giants like Bristol Myers Squibb and Sanofi. Can it last? Read...
Recent Comments